Crocetin Alleviates Inflammation in MPTP-Induced Parkinson’s Disease Models through Improving Mitochondrial Functions

Figure 1

Crocetin ameliorates MPTP-induced motor activity impairments. C57BL/6 mice treated with MPTP (25 mg/kg/d, 5 days, i.p.) were orally administered with crocetin for 11 days. (a) The structure of crocetin. (b) Weight change was monitored throughout the experiment. Outcomes of the rotarod performance test (c) and hanging performance (d) on day 8 and day 9. Bar graphs reveal the latency to fall in seconds (s). (e) Time to turn and total time in pole test was recorded on day 5 after the cease of MPTP treatment. (f) The total time of forced swimming was recorded. (g) Western blot determination of tyrosine hydroxylase (TH) expression levels in the striatum of each group. Data are expressed as the mean ± standard deviation, and statistical analysis was performed using a one-way analysis of variance followed by Tukey’s post hoc test. , versus normal; , versus MPTP, n = 8 mice in each group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)